|Day Low/High||16.50 / 17.10|
|52 Wk Low/High||7.65 / 15.84|
First -in-Class Oral Tryptophan Hydroxylase Inhibitor to be Considered for Approval in Europe for the Treatment of Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy
Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the August 18th expiration.
Sotagliflozin Demonstrates Statistically Significant Benefit in Primary Endpoint
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2018 expiration.
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Conference Call and Webcast to Follow
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
First-In-Class: Tryptophan Hydroxylase Inhibitor
Here are some names that have caught our eye.
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lexicon Pharmaceuticals, Inc. , where a total volume of 6,103 contracts has been traded thus far today, a contract volume which is representative of approximately 610,300 underlying shares (given that every 1 contract represents 100 underlying shares).
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AYR, CRCM, TG Downgrades: ADPT, AMZN, ANGI, ARNC, BKD, BWXT, CAJ, CALX, CSGP, EMR, HZO, LXRX, MNK, MYGN, NTRA, PBI, TCO, TRI Initiations: PFGC Read on to get TheStreet Quant Ratings' detailed report:
The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 2,011,299 share increase in total short interest for Lexicon Pharmaceuticals, Inc. , to 14,608,790, an increase of 15.97% since 09/15/2016.
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the August 19th expiration.
Here's a technical look at how to trade seven stocks rising on unusual volume.
Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a weak on high relative volume candidate